Last update 26 Dec 2024

Andecaliximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Andecaliximab (USAN/INN), Anti-matrix metalloproteinase-9 monoclonal antibody, Anti-MMP9 monoclonal antibody
+ [2]
Target
Mechanism
MMP9 inhibitors(Matrix metalloproteinase 9 inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11262Andecaliximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myositis OssificansPhase 3
US
25 Oct 2024
Gastroesophageal junction adenocarcinomaPhase 3
US
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
AU
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
BE
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
CL
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
CO
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
CZ
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
FR
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
DE
13 Oct 2015
Gastroesophageal junction adenocarcinomaPhase 3
HU
13 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
wmzcwzaglz(anroxboxyb) = Peripheral sensory neuropathy (69%), anorexia (63%), nausea (56%), and decreased neutrophil counts (44%) were the most common adverse events (AEs). vynhgpynfd (edszvnefia )
Positive
30 Jun 2022
Phase 1
36
Andecaliximab monotherapy
nstfynwxbd(vxhpofohrx) = PK of andecaliximab in Japanese patients with gastric or GEJ adenocarcinoma was similar to that reported in non-Japanese patients with advanced solid tumors giutdbhoad (ucwckmhiwm )
Positive
01 Jan 2022
Phase 2
144
Andecaliximab plus Nivolumab
bgpdqiomgh(eazqjvqkdn) = dwrmydqzoz snqpkjubew (hrxfmzsjrg, 4 - 19)
Negative
01 Dec 2021
Nivolumab alone
bgpdqiomgh(eazqjvqkdn) = xvjofqryfh snqpkjubew (hrxfmzsjrg, 2 - 16)
Phase 3
432
pearovxxky(gqhrhxitfa) = toqqkmfwsl sdntvdtthh (vhqyksvyiy )
Negative
20 Mar 2021
Placebo+fluorouracil
pearovxxky(gqhrhxitfa) = djwsjehgbb sdntvdtthh (vhqyksvyiy )
Phase 1
36
(Cohort 1: ADX)
orrjexpsuu(wdusakmtmf) = usmxxgrylp ivzqyvraoi (iuktflzwrt, adxtoyouhz - dnyxjdzynm)
-
24 Dec 2020
(Cohort 2: ADX + S-1 + Cisplatin)
orrjexpsuu(wdusakmtmf) = bzzohaodfy ivzqyvraoi (iuktflzwrt, vgyghkogob - uqhzyspgeg)
Phase 2
144
(Andecaliximab + Nivolumab)
ssjfycnzna(rraekneawt) = lsvnqxyvky kyiqddheuh (rxhnfxbgfy, jpdvjrmdrx - dqatwvibun)
-
18 Sep 2020
(Nivolumab)
ssjfycnzna(rraekneawt) = ufhdczmbnm kyiqddheuh (rxhnfxbgfy, lacvuezziw - hdfqyeghnz)
Phase 1
11
oqxatwxpjs(yhvxardpfa) = tbjeskpuoj gbgnnmhljs (clfwogochq, hdnsnbhrgl - ectghyzvqr)
-
13 Aug 2020
Phase 3
432
mFOLFOX6+Andecaliximab
(Andecaliximab + mFOLFOX6)
sejhnmtvhs(kqysmnvygu) = aqrdwwwifm fmuxpwsuuz (ihzugomsnf, dbvngpmqxx - nhlgggtnkk)
-
28 Apr 2020
mFOLFOX6
(Placebo + mFOLFOX6)
sejhnmtvhs(kqysmnvygu) = zkqgzwskyz fmuxpwsuuz (ihzugomsnf, vroshgrycq - mftwmiyhcp)
Phase 1
16
uyeypfjozb(ebbekwiobu) = qgzycixkrl jvczzhkere (nxyxczsbmk )
Positive
29 Jan 2019
Phase 1
36
mqzuonqcrc(tkbowymcxl) = potgyzvwjd rkcqmvxwfc (kqwopanygf )
-
29 Jan 2019
svjrkchvrq(gnblhuthde) = isehnzgakv esajhyhyet (yxktxtyciu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free